W. Va. Code R. § 24-1-3

Current through Register Vol. XLI, No. 50, December 13, 2024

Section 24-1-3 - Definitions

3.1. Affiliate. -- A member of a group of 2 or more fully accredited health care institutions legally united by an agreement of affiliation, conceived to enhance the potential of all participants in the provision of health care and medical education.

3.2. AOA. -- American Osteopathic Association

3.3. Approved program of post-graduate clinical training. -- A program of clinical training approved by, or subject to approval by, the American Osteopathic Association or approved by the Accreditation Council for Graduate Medical Education for the purposes of intern or resident training;

3.4. Board. -- The West Virginia Board of Osteopathic Medicine established in W. Va. Code § 30-14-1et seq.

3.5. COMLEX-USA. -- The Comprehensive Osteopathic Medical Licensing Examination of the United States.

3.6. Controlled substances. -- Drugs that are classified by federal or state law in Schedules I, II, III, IV, or V, as defined in W. Va. Code §§ 60A-2-204 through 212.

3.7. FCVS -- The Federation of State Medical Boards' Credentials Verification Service.

3.8. Immediate family -- A person within one degree of kinship of a physician or any relative living in the physician's household.

3.9. Opioid -- Natural and semi-synthetic derivatives of the opium poppy, as well as similar synthetic compounds that have analgesic or pain-relieving properties because of their effects in the central nervous system. These include, but are not limited to, codeine, morphine, hydromorphone, hydrocodone, oxycodone, methadone and fentanyl.

3.10. NBOME. -- The National Board of Osteopathic Medical Examiners.

3.11. Probation. -- Conditions and requirements imposed upon a licensee for a period of time that the board, in its discretion, determines to be justified under any provision of law. A licensee placed on probation may continue to practice subject to limitations imposed by the board, including the requirement that the licensee appear before the Board, or an officer or agent of the Board at such times and places as are designated by the Board. A licensee may be placed on probation without a previous or concurrent suspension or revocation of his or her license.

3.12. Risk Assessment and Responsible Prescribing of Controlled Substances -- Drug diversion training, best-practice prescribing of controlled substances training, and training on prescribing and administering an opioid antagonist which shall include all of the following components:

3.12.1. Risk Assessment and responding to drug diversion and drug seeking behavior, including:

3.12.1.a. Tools for conducting routine patient assessments for risk factors associated with drug diversion, misuse or abuse, and identification of substance use disorder treatment referral resources;

3.12.1.b. West Virginia specific statistics on prescription drug abuse and resulting deaths;

3.12.1.c. Identification of diversion and drug seeking tactics and behaviors;

3.12.1.d. Best practices for assessing, treating, and referring patients suspected of drug seeking behavior, diversion, or substance use disorder;

3.12.1.e. Introduction to Medication for Opioid Use Disorder (MOUD) and training on the effectiveness of MOUD treatment including the use of full opioid agonist, partial opioid agonist, and opioid antagonists; and

3.12.1.f. Training on the impacts of stigma on treatment effectiveness including the concept of addiction as a chronic disease.

3.12.2. Responsible prescribing of controlled substances, including:

3.12.2.a. Compliance with state and federal controlled substances laws, rules, and regulations, including the Opioid Reduction Act, W. Va. Code § 16-54-1et seq.;

3.12.2.b. Registering with and utilization of the West Virginia Controlled Substances Monitoring Program established in W. Va. Code § 60A-9-1et seq.;

3.12.2.c. Epidemiology of chronic pain in West Virginia and misuse of opioids;

3.12.2.d. Indication for opioids in chronic pain treatment including general characteristics, toxicities, and drug interactions;

3.12.2.e. Examination of patient evaluation and risk assessment and tools to assess risk and monitor benefits;

3.12.2.f. Initiation and ongoing management of chronic pain patients treated with opioid based therapies, including treatment objectives; monitoring and periodic review; referrals and consultations; informed consent; prescription of controlled substance agreements, urine screens and pill counts; patient education on safe use, storage, and disposal of opioids; discontinuation of opioids for pain due to lack of benefits or increased risks; documentation and medical records;

3.12.2.g. Presentation of a case study of a patient with chronic pain; and

3.12.2.h. Best practices for managing patients with active prescriptions for more than one controlled substance.

3.12.3. Training on prescribing and administering an opioid antagonist.

3.13. Website or Board's website -- The set of related web pages operated by or on behalf of the West Virginia Board of Osteopathic Medicine located at the domain name www.wvbdosteo.org or at any successor domain name published by the Board.

W. Va. Code R. § 24-1-3